SCHEMBL7184953

SCHEMBL7184953

CCOC(=O)C(C(=O)c1c(C)cccc1Cl)c1ccccc1.O=[PH3]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.43
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
NPC1 O15118 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 2/20 0.39
TRPM4 Q8TD43 1/20 0.38
CASP1 P29466 1/20 0.38
RORC P51449 1/20 0.38
PIN1 Q13526 1/20 0.38
MAPT P10636 2/20 0.37
ALDH1A1 P00352 2/20 0.37
ALOX5 P09917 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27499665 0.95 MMP8 (0.50) MMP8L3MBTL1CA12CA1CA2
SCHEMBL7175563 0.93 MMP8 (0.54) MMP8L3MBTL1CA12CA1CA2
SCHEMBL7182317 0.91 MMP8 (0.41) MMP8L3MBTL1NPC1TRPM4MAPT
SCHEMBL7185347 0.91 L3MBTL1 (0.43) MMP8L3MBTL1NPC1SMN1; SMN2MEN1
SCHEMBL7174643 0.91 MMP8 (0.56) MMP8L3MBTL1CA12CA1CA2
SCHEMBL7185196 0.89 L3MBTL1 (0.41) MMP8L3MBTL1NPC1SMN1; SMN2TSHR
SCHEMBL7174628 0.89 ALDH1A1 (0.40) MMP8L3MBTL1NPC1SMN1; SMN2MEN1
SCHEMBL7182786 0.89 ELANE (0.43) MMP8L3MBTL1NPC1SMN1; SMN2MEN1
SCHEMBL7188400 0.88 NPC1 (0.42) MMP8L3MBTL1NPC1SMN1; SMN2TSHR
SCHEMBL7180891 0.87 LMNA (0.43) NPC1SMN1; SMN2TSHRALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MMP8 4404/4885L3MBTL1 302/4885CA12 1552/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MMP8 4586/4885L3MBTL1 126/4885CA12 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.